Alevin Therapeutics Ltd – a spin-out from the University of Nottingham was founded in March 2022 with the aim of developing safe and effective medicines for patients with life-threatening diseases. They are developing a platform of novel small molecule RGD integrin inhibitors with superior drug-like qualities. It aims to develop assets for therapeutic applications based on their RGD Integrin platform; in particular idiopathic pulmonary fibrosis (IPF), liver and kidney disease and cancer. The most advanced programme is close to a development candidate which we seek to take forward as an inhaled IPF drug.
|University of Nottingham
March 15, 2023